Tag: biosimilar hormones market trends

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

2024-2033 Biosimilar Hormones Market: What Growth Rate is Predicted?

In recent times, there has been an exponential rise in the dimension of the biosimilar hormones market. It is projected that it will expand from $3.9 billion in 2023 to $4.98 billion in 2024, indicating a compound annual growth rate (CAGR) of 27.5%. Factors such as increased chronic disease prevalence, an aging population increase, heightened awareness about biosimilar hormones, and broader healthcare access have all contributed to the historic period’s growth.

The market for biosimilar hormones is predicted to witness immense growth in the following years, reaching a value of $11.77 billion in 2028 at a compound annual growth rate (CAGR) of 24.0%. The anticipated surge during this period can be attributed to a variety of factors including the expansion of hormone targets, increased patient acceptance, advancements in manufacturing processes, governmental backing, a rise in clinical trial data, and broadened healthcare accessibility. Notable trends projected for this interval comprise of personalized hormone substitution, product launches, pricing and accessibility considerations, and a focus on patient-oriented care.

Claim Your Free Sample of the Global Biosimilar Hormones Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp

What Aspects Are Driving the Expansion of the biosimilar hormones Market?

The hormone biosimilars market is being driven by the widespread nature of growth hormone and metabolic hormone deficiencies. Over time, the methodologies for treating hormone-related conditions have evolved, and the widespread existence of these deficiencies has heightened demand in the hormone biosimilars market. For example, the British Medical Journal, a UK-based medical trade journal that is peer-reviewed, reported in January 2022 that it is estimated that the prevalence of growth hormone deficiency (GHD) in children falls between 1 in 3500 to 1 in 10000 globally. Moreover, a Medscape report from June 2022 projected an anticipated 6,000 adults in the USA to be diagnosed with growth hormone (GH) deficiency. The hormone biosimilar market’s growth is being propelled by the imperative to treat patients with these hormonal deficiencies.

What Are the Significant Segments of the Biosimilar Hormones Market?

1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types

2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications

3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics

What Trends Are Influencing the Evolution of the Biosimilar Hormones Market?

Renowned entities in the biosimilar hormones market are engaging in strategic maneuvers like debuting new products in previously unexplored areas to make the medication accessible to a broader demographic. The firms are intent on rolling out their products in diverse locales to spur sales and heighten profit margins. As an illustration, in February 2022, Alvotech Holdings S.A., a biopharmaceutical organisation based in Luxembourg that excels in the manufacture of biosimilar drugs, announced a collaboration with Fuji Pharma Co. Ltd., an established pharmaceutical firm in Japan. This collaboration is aimed at the development of biosimilar drug candidates within the Japanese market. Consequently, both corporations have resolved to incorporate new aspects into their strategic partnership for the production and marketing of biosimilar medicines in Japan.

Order Now for Fast Delivery of Your Biosimilar Hormones Market Report!

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Which Geographic Areas Are Influencing the Growth of the Biosimilar Hormones Market?

North America was the largest region in the biosimilar hormones market in 2023. The regions covered in the biosimilar hormones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The Biosimilar Hormones Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the biosimilar hormones market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Biosimilar Hormones Market Include

1. Biosimilar Hormones Market Executive Summary

2. Biosimilar Hormones Market Segments

3. Biosimilar Hormones Market Size And Template Market Growth Rate

4. Key Biosimilar Hormones Market Trends

5. Major Biosimilar Hormones Market Drivers

……

25. Key Mergers And Acquisitions In The Biosimilar Hormones Market

26. Top Biosimilar Hormones Companies

27. Biosimilar Hormones Market Opportunities And Strategies

28. Biosimilar Hormones Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Hormonal Contraceptives Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

Biosimilar Growth Hormones Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Parathyroid Hormone Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The biosimilar hormones market has witnessed a remarkable surge in recent years, propelled by various factors contributing to its expansion and innovation:

• Market size surged from $3.9 billion in 2023 to $4.98 billion in 2024, at a CAGR of 27.5%
• Historic growth attributed to rising prevalence of chronic diseases, aging population, growing awareness of biosimilar hormones, and expanded healthcare access

A Glimpse into the Future: Projections and Trends

The market is poised for exponential growth in the coming years, with forecasts indicating substantial expansion:

• Expected to reach $11.77 billion by 2028, with a CAGR of 24.0%
• Factors driving growth include expanding hormone targets, growing patient acceptance, advances in manufacturing, government support, clinical trial data, and enhanced healthcare access
• Major trends include personalized hormone replacement, product launches, pricing and access, and patient-centric care

Fueling Demand: The Prevalence of Hormonal Deficiencies

The rising prevalence of deficiencies in growth hormones and metabolic hormones serves as a catalyst for market growth:

• Treatments for hormone-related conditions evolving over the years
• Prevalence data highlighting the need:
  • GH deficiency (GHD) in children: 1 in 3500 to 1 in 10000 globally
  • Growth hormone (GH) deficiency in adults: approximately 6,000 cases expected in the USA
• Growing need to address hormonal deficiencies driving demand for biosimilar hormones

View More On The Biosimilar Hormones Market Report 2024 – https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Key Players Driving Innovation

Major companies spearheading innovations in the biosimilar hormones market include:

• Teva Pharmaceutical Industries Ltd.
• Gedeon Richter Plc.
• Intas Pharmaceuticals Ltd.
• Biocon Limited
• Mylan
• Sanofi
• Sandoz (Novartis)
• LG Life Sciences
• Ferring Pharmaceuticals
• GC Pharma

Novo Nordisk’s Sogroya Injection: A Paradigm Shift

Novo Nordisk’s groundbreaking Sogroya (somapacitan-beco) injection marks a significant milestone in the market:

• FDA approval for pediatric use, expanding its indications
• Sogroya addresses growth hormone deficiency (GHD) in children aged 2.5 years and older
• The sole once-weekly growth hormone (GH) therapy for both children and adults
• Approval based on phase 3 REAL4 trial findings, showcasing its efficacy in pediatric patients

Market Segmentation

The biosimilar hormones market is segmented based on various parameters:

1. By Type:
   • Teriparatide Biosimilars
   • Follitropin Alfa Biosimilars
   • Insulin Biosimilars
   • Somatropin Biosimilars
   • Other Types
2. By Application:
   • Research & Biotechnology
   • Diagnostics
   • Biocatalysts
   • Therapeutics
   • Other Applications
3. By Distribution Channel:
   • Hospital And Retail Pharmacy
   • Online Pharmacy/ePharmacy
   • Specialty Clinics

Regional Dynamics: North America Takes the Lead

• North America emerged as the largest region in the biosimilar hormones market in 2023

As the market continues to evolve and expand, stakeholders are poised to witness unprecedented growth opportunities. With a focus on innovation, accessibility, and patient-centric care, the biosimilar hormones market is set to reshape the landscape of hormonal therapies, offering new avenues for treatment and improving the quality of life for patients worldwide.

Request A Sample Of The Global Biosimilar Hormones Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=3432&type=smp